Jaguar Health stock: Q3 revenue falls as loss narrows
Published on 11/19/2026 at 02:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQuarterly results reshape Jaguar's outlook
- Jaguar shifted its commercial model toward licensing while keeping manufacturing operations for key products.
- The company is targeting a mid-2027 regulatory filing for crofelemer in microvillus inclusion disease.
- Debt reduction and lower operating expenses improved the quarter, but product revenue declined sharply.
Jaguar Health reported third-quarter 2026 results on November 16, highlighting a narrower loss, lower debt and a sharper focus on rare gastrointestinal diseases. The company said its late-stage crofelemer program remains on track for a planned New Drug Application filing for microvillus inclusion disease in mid-2027.
According to Jaguar Health's release, total revenue fell 24.0 percent year over year to USD 2.343 million for the quarter ended September 30. Product revenue dropped 81.9 percent to USD 551,000, while license and grant revenue rose to USD 1.792 million from USD 42,000 a year earlier.
Loss narrows as costs fall
Jaguar's loss from operations narrowed to USD 6.023 million from USD 7.238 million in the prior-year quarter. Net loss narrowed to USD 5.830 million from USD 9.648 million, while non-GAAP recurring EBITDA loss improved to USD 5.032 million from USD 9.025 million.
The cost structure changed substantially after the company licensed U.S. marketing rights for Mytesi and Canalevia-CA1 to Future Pak. Jaguar remains the manufacturer and supplies the products at cost-plus terms, while Future Pak receives U.S. revenue under the royalty-free arrangement. Jaguar said its outstanding debt balance fell by USD 10.1 million during the quarter, including the cancellation of the Streeterville New Note after a common-stock exchange.
Rare disease pipeline takes priority
Jaguar and its family companies are concentrating human development efforts on crofelemer powder for oral solution in intestinal failure disorders, including microvillus inclusion disease and short bowel syndrome. The planned mid-2027 filing is the next major regulatory milestone for investors, with development execution and financing capacity remaining central to the outlook.
Business model and market position
Jaguar Health develops plant-derived prescription therapies for gastrointestinal diseases affecting human and animal patients. Its human portfolio includes Mytesi, an approved treatment for noninfectious diarrhea in adults with HIV/AIDS, while its pipeline targets rare intestinal failure disorders. The company also develops animal-health products and plant-derived medicines through its affiliated businesses.
Jaguar Health at a glance
- Company: Jaguar Health, Inc.
- ISIN: US47010C8543
- Ticker: JAGX
- Home exchange: Nasdaq
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters: San Francisco, United States
The U.S. healthcare market remains the relevant market environment for Jaguar Health, alongside the S&P 500.
More news and analyses on Jaguar Health stock are available here.
